The Perspective of Global Eradication of Poliomyelitis: Polio and Non-polio Enteroviruses and Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 7016
Special Issue Editors
2. Department of Organization and Technology of Production of Immunobiological Preparations, Institute for Translational Medicine and Biotechnology, First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
Interests: poliomyelitis eradication; poliomyelitis; polioviruses; poliovirus vaccine; non-polio enteroviruses; epidemiological surveillance
Interests: evolution and taxonomy of polio- and non-polio enteroviruses; non-polio enterovirus emerging human infections: enterovirus meningitis; hand-foot-and-mouth disease
Special Issue Information
Dear Colleagues,
The eradication of wild poliovirus has been a goal for over 30 years. Despite the outstanding progress of the WHO Global Polio Eradication Initiative in the elimination of wild polioviruses almost all over the world, the final eradication of poliomyelitis has not yet been achieved, due to both organizational barriers and the clinical, epidemiological and biological properties of poliovirus, primarily the peculiarities of its evolution. The main challenge following the impressive success in eradicating wild polioviruses with Sabin Oral Poliovirus Vaccine (OPV) has been the emergence of outbreaks caused by viruses derived from the same vaccine, which have neurovirulence and transmissibility—VDPV. The epidemiological significance of VDPV is indistinguishable from wild polioviruses. The development and introduction of new, effective, genetically stable, safer vaccines that combine the best properties of traditional OPV and IPV poliovirus vaccines is urgently need. Apparently, polio immunization will never be stopped. Recently, a new type 2 monovalent vaccine from genetically modified Sabin strains (nOPV2) has been developed and put into use, following the approach of nOPV types 1 and 3, but their global impact remains to be seen.
A new threat is the emergence of non-polio enterovirus diseases, such as foot-and-mouth disease caused by enterovirus A71, acute flaccid myelitis caused by enterovirus 68. At present, the non-polio enterovirus threat is under vaccine control only in some countries around the world. The factors leading to the emergence of new enteroviral diseases remain poorly understood; the need for vaccines against non-polio enteroviral diseases has not been determined.
In this Special Issue, we would like to invite papers covering a wide range of topics and recent developments in all phases of the development of vaccines against polio and non-polio enterovirus infections. Providing epidemiological information on the circulation of polio and non-polio enteroviruses will help to justify the need for vaccines. The study of the immune response to the introduction of the vaccine will allow us to evaluate the effectiveness of the formation and the role of different types of immune protection.
Dr. Olga E. Ivanova
Prof. Dr. Alexander Lukashev
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- poliovirus
- non-polio enteroviruses
- acute flaccid paralysis
- polio vaccine
- non-polio enterovirus vaccine
- enterovirus types
- hand-foot-and-mouth disease
- acute flaccid myelitis
- enterovirus meningitis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
